Literature DB >> 11027817

Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population.

J Mossong1, C J O'Callaghan, S Ratnam.   

Abstract

We analysed measles antibody data from 1141 vaccinated Canadian children aged 4-16 years to investigate factors associated with seropositivity and magnitude of prevailing antibody titres. We used a mixed Bernoulli/log-gamma model which takes account of the possibility of primary vaccine failures, of censored observations due to the lower detection limit of antibody assays and of a potentially skewed distribution of the logarithm of titres. While controlling for all significant variables, we observed that measles antibody titres decline at a mean rate of 5.6% per annum (approximate 95% CI; 3.3-7.7) equivalent to a half life of 12 years. Further, we noted a detectable linear relationship with respect to age at immunisation such that the mean increase in measles antibody titre of an infant who responds to vaccination gained by delaying vaccination from 12 to 18 months of age is 11.1% (approximate 95% CI; 4.4-18.3).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027817     DOI: 10.1016/s0264-410x(00)00175-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

Review 1.  Sex-based differences in immune function and responses to vaccination.

Authors:  Sabra L Klein; Ian Marriott; Eleanor N Fish
Journal:  Trans R Soc Trop Med Hyg       Date:  2015-01       Impact factor: 2.184

2.  Assessment of the epidemiology and burden of measles in Southern Mozambique.

Authors:  Inácio Mandomando; Denise Naniche; Marcela F Pasetti; Lilian Cuberos; Sergi Sanz; Xavier Vallès; Betuel Sigauque; Eusébio Macete; Delino Nhalungo; Karen L Kotloff; Myron M Levine; Pedro L Alonso
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

3.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

4.  A population profile of measles susceptibility in Tianjin, China.

Authors:  Matthew L Boulton; Xiexiu Wang; Ying Zhang; JoLynn P Montgomery; Abram L Wagner; Bradley F Carlson; Yaxing Ding; Xiaoyan Li; Brenda Gillespie; Xu Su
Journal:  Vaccine       Date:  2016-05-03       Impact factor: 3.641

5.  Genetically defined race, but not sex, is associated with higher humoral and cellular immune responses to measles vaccination.

Authors:  Emily A Voigt; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Beth R Larrabee; Daniel J Schaid; Gregory A Poland
Journal:  Vaccine       Date:  2016-08-30       Impact factor: 3.641

6.  A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

7.  A target site for template-based design of measles virus entry inhibitors.

Authors:  Richard K Plemper; Karl J Erlandson; Ami S Lakdawala; Aiming Sun; Andrew Prussia; Jutatip Boonsombat; Esin Aki-Sener; Ismail Yalcin; Ilkay Yildiz; Ozlem Temiz-Arpaci; Betul Tekiner; Dennis C Liotta; James P Snyder; Richard W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-31       Impact factor: 11.205

Review 8.  Measles control--can measles virus inhibitors make a difference?

Authors:  Richard K Plemper; James P Snyder
Journal:  Curr Opin Investig Drugs       Date:  2009-08

9.  Gender effects on humoral immune responses to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Margaret A K Ryan; Gregory A Poland
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

10.  An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model.

Authors:  Stefanie A Krumm; Dan Yan; Elise S Hovingh; Taylor J Evers; Theresa Enkirch; G Prabhakar Reddy; Aiming Sun; Manohar T Saindane; Richard F Arrendale; George Painter; Dennis C Liotta; Michael G Natchus; Veronika von Messling; Richard K Plemper
Journal:  Sci Transl Med       Date:  2014-04-16       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.